CCP
REGN icon

Corient Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Corient Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.12M Hold
1,896
– – 0.08% 200
2022
Q2 		$1.12M Buy
1,896
+31
+2% +$20.1K 0.09% 203
2022
Q1 		$1.3M Buy
1,865
+479
+35% +$303K 0.09% 206
2021
Q4 		$875K Buy
1,386
+41
+3% +$25.2K 0.06% 245
2021
Q3 		$814K Sell
1,345
-212
-14% -$132K 0.06% 249
2021
Q2 		$870K Buy
1,557
+180
+13% +$91.2K 0.06% 233
2021
Q1 		$652K Buy
1,377
+35
+3% +$17K 0.06% 267
2020
Q4 		$649K Sell
1,342
-409
-23% -$221K 0.06% 234
2020
Q3 		$980K Sell
1,751
-105
-6% -$63.7K 0.11% 167
2020
Q2 		$1.16M Buy
1,856
+729
+65% +$414K 0.14% 136
2020
Q1 		$550K Buy
1,127
+217
+24% +$89.5K 0.09% 201
2019
Q4 		$342K Buy
+910
New +$306K 0.04% 332

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Corient Capital Partners's REGN Position: Q3 2022 in Review

Corient Capital Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2022 at 1,896 shares worth $1.12M. The position accounts for 0.08% of the portfolio, ranked #200.

Corient Capital Partners first reported a position in REGN in Q4 2019 and has held it in 12 quarters since. The position peaked at $1.3M in Q1 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

  • Corient Capital Partners held 1,896 shares of Regeneron Pharmaceuticals worth $1.12M as of Q3 2022.
  • Corient Capital Partners left its Regeneron Pharmaceuticals share count unchanged in Q3 2022.
  • Regeneron Pharmaceuticals made up 0.08% of Corient Capital Partners's portfolio in Q3 2022, its #200 holding.
  • Corient Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 12 quarters since.
  • Corient Capital Partners's Regeneron Pharmaceuticals position peaked at $1.3M in Q1 2022.
  • 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.